MCID: ALC009
MIFTS: 53

Alcoholic Liver Cirrhosis

Categories: Endocrine diseases, Gastrointestinal diseases, Liver diseases

Aliases & Classifications for Alcoholic Liver Cirrhosis

MalaCards integrated aliases for Alcoholic Liver Cirrhosis:

Name: Alcoholic Liver Cirrhosis 12 75 15 38 17
Alcoholic Cirrhosis 12 55 15
Portal Cirrhosis 12 55 72
Alcoholic Cirrhosis of Liver 12 33
Liver Cirrhosis, Alcoholic 44 72
Laennec's Cirrhosis, Alcoholic 12
Laennec's Cirrhosis 12

Classifications:



External Ids:

Disease Ontology 12 DOID:14018
ICD9CM 35 571.2
MeSH 44 D008104
NCIt 50 C34782
SNOMED-CT 68 75393009
ICD10 33 K70.3
UMLS 72 C0023891 C1622502

Summaries for Alcoholic Liver Cirrhosis

MalaCards based summary : Alcoholic Liver Cirrhosis, also known as alcoholic cirrhosis, is related to alcoholic pancreatitis and esophageal varix, and has symptoms including icterus An important gene associated with Alcoholic Liver Cirrhosis is ADH1B (Alcohol Dehydrogenase 1B (Class I), Beta Polypeptide), and among its related pathways/superpathways are Metabolism and Cytochrome P450 - arranged by substrate type. The drugs Losartan and Angiotensin II have been mentioned in the context of this disorder. Affiliated tissues include Liver, liver and skin, and related phenotype is liver/biliary system.

Wikipedia : 75 Cirrhosis, also known as liver cirrhosis or hepatic cirrhosis, is a condition in which the liver does... more...

Related Diseases for Alcoholic Liver Cirrhosis

Diseases related to Alcoholic Liver Cirrhosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 361)
# Related Disease Score Top Affiliating Genes
1 alcoholic pancreatitis 31.0 CYP2E1 ALDH2 ADH1B
2 esophageal varix 30.9 F2 ALB
3 peritonitis 30.8 F2 CXCL8 ALB
4 portal hypertension 30.8 GPT F2 ALB
5 antipyrine metabolism 30.7 F2 ALB
6 hepatic coma 30.6 GPT F2 ALB
7 alcoholic neuropathy 30.5 ALDH2 ADH4
8 alcohol dependence 30.3 CYP2E1 ALDH2 ADH4 ADH1C ADH1B
9 schistosomiasis 30.2 GSTM1 F2 ALB
10 endocarditis 30.2 F2 CXCL8 ALB
11 hepatitis a 29.9 GPT F2 ALB
12 cholecystitis 29.9 GPT F2 ALB
13 cholangitis 29.9 GPT F2 ALB
14 gastrointestinal system disease 29.9 F2 CXCL8 ALB
15 hepatic encephalopathy 29.9 SLC17A5 GPT F2 ALB
16 hepatitis e 29.8 GPT F2 ALB
17 viral hepatitis 29.7 SLC17A5 GPT F2 ALB
18 wilson disease 29.7 GPT F2 ALB
19 esophageal cancer 29.5 GSTM1 CXCL8 ALDH2 ALB ADH1B
20 fatty liver disease 29.5 SLC17A5 PNPLA3 CYP2E1 CXCL8
21 liver cirrhosis 29.4 SLC17A5 HGF GPT F2 CYP2E1 ALDH2
22 alcoholic hepatitis 29.3 SLC17A5 GPT F2 CYP2E1 CXCL8 ALB
23 bilirubin metabolic disorder 29.3 SLC17A5 GPT F2 ALB
24 hepatitis b 29.2 SLC17A5 GPT F2 ALB
25 infantile liver failure syndrome 1 29.1 SLC17A5 GPT F2 ALB
26 choledocholithiasis 29.1 SLC17A5 GPT F2 ALB
27 acute liver failure 28.7 SLC17A5 HGF GPT F2 ALB
28 liver disease 28.3 SLC17A5 PNPLA3 HGF GPT F2 CYP2E1
29 obstructive jaundice 28.3 SLC17A5 HGF GPT F2 CXCL8 ALB
30 varicose veins 10.6
31 non-a-e hepatitis 10.6 F2 ALB
32 alcohol use disorder 10.5
33 methanol poisoning 10.5 CYP2E1 ADH1C ADH1B
34 sister chromatid exchange, frequency of 10.5 GSTM1 CYP2E1 ALDH2
35 fournier gangrene 10.5 F2 ALB
36 abdominal tuberculosis 10.5 F2 ALB
37 scabies 10.4 GSTM1 CXCL8
38 esophageal disease 10.4 ALDH2 ALB ADH1B
39 pyuria 10.4 CXCL8 ALB
40 noma 10.4 CXCL8 ALB
41 eccrine adenocarcinoma 10.4 F2 AHSG
42 hepatoportal sclerosis 10.3 GPT F2
43 capillary leak syndrome 10.3 CXCL8 ALB
44 epstein-barr virus hepatitis 10.3 F2 ALB AHSG
45 hepatocellular carcinoma 10.3
46 splenic disease 10.3 F2 ALB
47 dengue hemorrhagic fever 10.3 F2 CXCL8 ALB
48 hepatitis c virus 10.3
49 hepatorenal syndrome 10.3
50 ascending cholangitis 10.2 F2 ALB

Comorbidity relations with Alcoholic Liver Cirrhosis via Phenotypic Disease Network (PDN): (show all 24)


Acquired Thrombocytopenia Active Peptic Ulcer Disease
Acute Cystitis Acute Kidney Failure
Acute Pancreatitis Alcoholic Cardiomyopathy
Alcoholic Gastritis Alcoholic Hepatitis
Alcoholic Neuropathy Chronic Congestive Splenomegaly
Deficiency Anemia Esophageal Varix
Familial Atrial Fibrillation Fatty Liver Disease
Heart Disease Hepatic Encephalopathy
Hepatocellular Carcinoma Hepatorenal Syndrome
Hypersplenism Iron Deficiency Anemia
Portal Hypertension Protein-Energy Malnutrition
Respiratory Failure Urea Cycle Disorder

Graphical network of the top 20 diseases related to Alcoholic Liver Cirrhosis:



Diseases related to Alcoholic Liver Cirrhosis

Symptoms & Phenotypes for Alcoholic Liver Cirrhosis

UMLS symptoms related to Alcoholic Liver Cirrhosis:


icterus

MGI Mouse Phenotypes related to Alcoholic Liver Cirrhosis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 liver/biliary system MP:0005370 9.1 ALB ALDH2 CYP2E1 HGF PNPLA3 SOD2

Drugs & Therapeutics for Alcoholic Liver Cirrhosis

Drugs for Alcoholic Liver Cirrhosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 125)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Losartan Approved Phase 4 114798-26-4 3961
2
Angiotensin II Approved, Investigational Phase 4 11128-99-7, 68521-88-0, 4474-91-3 172198
3
Mannitol Approved, Investigational Phase 4 69-65-8 453 6251
4
Sorafenib Approved, Investigational Phase 4 284461-73-0 216239 406563
5
Propranolol Approved, Investigational Phase 4 525-66-6 4946
6
Spironolactone Approved Phase 4 1952-01-7, 52-01-7 5833
7
Isoleucine Approved, Investigational, Nutraceutical Phase 4 443-79-8, 73-32-5 6306
8 Angiotensinogen Phase 4
9 Angiotensin II Type 1 Receptor Blockers Phase 4
10 Giapreza Phase 4
11 Angiotensin Receptor Antagonists Phase 4
12 Liver Extracts Phase 4
13 valine Phase 4
14 leucine Phase 4
15 Protein Kinase Inhibitors Phase 4
16 Antihypertensive Agents Phase 4
17 Hormones Phase 4
18 Diuretics, Potassium Sparing Phase 4
19 Natriuretic Agents Phase 4
20 Mineralocorticoid Receptor Antagonists Phase 4
21 Mineralocorticoids Phase 4
22 Adrenergic beta-Antagonists Phase 4
23 diuretics Phase 4
24 Adrenergic Antagonists Phase 4
25 Hormone Antagonists Phase 4
26 Adrenergic Agents Phase 4
27 Anti-Arrhythmia Agents Phase 4
28 Vasodilator Agents Phase 4
29 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4
30
Baclofen Approved Phase 3 1134-47-0 2284
31
Tacrolimus Approved, Investigational Phase 3 104987-11-3 445643 439492 6473866
32
Sirolimus Approved, Investigational Phase 3 53123-88-9 6436030 5284616 46835353
33
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
34
Everolimus Approved Phase 3 159351-69-6 6442177 70789204
35
Sofosbuvir Approved Phase 3 1190307-88-0 45375808
36
Ledipasvir Approved Phase 3 1256388-51-8 67505836
37
Terlipressin Approved, Investigational Phase 3 14636-12-5 72081
38
Ethanol Approved Phase 3 64-17-5 702
39
Naltrexone Approved, Investigational, Vet_approved Phase 3 16590-41-3 5360515
40
tannic acid Approved Phase 3 1401-55-4
41
Iron Approved, Experimental Phase 3 15438-31-0, 7439-89-6 23925 27284
42
Benzocaine Approved, Investigational Phase 3 94-09-7, 1994-09-7 2337
43 Antiviral Agents Phase 3
44 Antifungal Agents Phase 3
45 Immunosuppressive Agents Phase 3
46 Immunologic Factors Phase 3
47 Calcineurin Inhibitors Phase 3
48 Ledipasvir, sofosbuvir drug combination Phase 3
49 Nutrients Phase 3
50 Micronutrients Phase 3

Interventional clinical trials:

(show top 50) (show all 64)
# Name Status NCT ID Phase Drugs
1 Losartan in the Prevention of Sodium Retention and Ascites in Liver Cirrhosis – a Prospective Randomized Long-Term Study Unknown status NCT00239096 Phase 4 losartan (drug)
2 Treatment of Sarcopenia Improves the Muscle Mass and Muscle Strength of Patients With Liver Cirrhosis- Child C: A Randomized Double Blind Control Trial Recruiting NCT03633279 Phase 4 Branched chain amino acid;Placebo
3 Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma Recruiting NCT02733809 Phase 4 Sorafenib
4 Hemodynamic Effects of Chronic Administration of Spironolactone, Propranolol and Their Association in Alcoholic Cirrhotic Patients Terminated NCT00188045 Phase 4 Propranolol - Spironolactone
5 Multicenter, Prospective, Open-label, Controlled, Randomized, Parallel Groups Study to Evaluate the Renal Function of Adult Liver Transplant Recipients Treated With Two Everolimus-based Immunosuppressive Regimens (Tacrolimus Withdrawal vs. Minimization) Until 12 Months Post-transplant, With a 6-months Follow-up Completed NCT02115113 Phase 3 Everolimus;Tacrolimus
6 Exploring the Efficacy and Biobehavioural Basis of Baclofen in the Treatment of Alcoholic Liver Disease Completed NCT01711125 Phase 3 Baclofen 30mg/day;Baclofen 75mg/day;Placebo
7 The Effects of Anti-Viral Therapy on the Clinical Status, Quality of Life, and Survival of Patients With Decompensated Cirrhosis Due to Hepatitis C Genotype 1 Infection Completed NCT02597166 Phase 3 Ledipasvir/Sofosbuvir
8 Comparison of Bovine Colostrum Versus Placebo in Treatment of Severe Alcoholic Hepatitis: A Randomized Double Blind Controlled Trial Recruiting NCT02473341 Phase 3 Bovine Colostrum;Placebo
9 Multicentre, Randomised, Double-blind, Placebo-controlled Trial of Nalmefene in Patients With Alcoholic Compensated Cirrhosis for the Treatment of Alcohol Dependence. Not yet recruiting NCT02824354 Phase 3 Nalmefene (Selincro®) 18 mg tablet;placebo
10 Influence of Iron Depletion by Phlebotomy on the Risk of Hepatocellular Carcinoma Occurrence in Patients With Compensated Alcoholic Cirrhosis. Prospective, Multicentre, Randomized Trial Terminated NCT01342705 Phase 3
11 International Randomized Study of Transarterial Chemoembolization Versus CyberKnife® for Recurrent Hepatocellular Carcinoma Withdrawn NCT01318200 Phase 3
12 The Evaluation of Effectiveness and Safety for New Therapy With Bone Marrow Derived Autologous Mesenchymal Stem Cell for Hepatic Failure Caused by Alcoholic Liver Cirrhosis Unknown status NCT01741090 Phase 2
13 Effects of Rifaximin Treatment in Patients With Acute Alcoholic Hepatitis: A Comparative Pilot Study Unknown status NCT02116556 Phase 2 Prednisone;Rifaximin
14 An Open-Label, Multi-Center, Single-Arm Study on Effectiveness and Safety of Stereotactic Body Radiotherapy (SBRT) Treating Hepatocellular Carcinoma Patients With CyberKnife Unknown status NCT02363218 Phase 2
15 A Parallel Group Randomized Open Blinded End Point Evaluation, Multicentric, Dose Escalation, Phase -II Study Assessing the Safety and Efficacy of Intraarterial (Hepatic) Ex-vivo Cultured Adult Allogenic Mesenchymal Stem Cells in Patients With Alcoholic Liver Cirrhosis Completed NCT01591200 Phase 2
16 Randomized Exploratory Clinical Trial to Evaluate the Safety and Effectiveness of Stem Cell Product in Alcoholic Liver Cirrhosis Patient. Completed NCT01875081 Phase 2
17 Maintaining Alcohol Abstinence in Alcoholic Patients With Liver Cirrhosis: Efficacy and Safety of Baclofen Administration in a Randomized Double Blind Controlled Study Completed NCT00525252 Phase 1, Phase 2 Baclofen;placebo
18 A Phase 2, Double-Blind, Randomized Study Evaluating the Safety, Tolerability, and Efficacy of GS-4997 in Combination With Prednisolone Versus Prednisolone Alone in Subjects With Severe Alcoholic Hepatitis (AH) Completed NCT02854631 Phase 2 Selonsertib;Prednisolone;Placebo
19 A Phase II, Double-blinded, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Vitalliver in Patients With Decompensated Cirrhosis Completed NCT00562783 Phase 2 Vitaliver;Placebo
20 Immune-inflammatory and Metabolic Effects of High Dose Furosemide Plus Hypertonic Saline Solution (HSS) Treatment in Cirrhotic Subjects With Refractory Ascite Completed NCT02821377 Phase 2 intravenous furosemide;Hypertonic saline solutions
21 Safety and Efficacy of Human Unbilical Cord Derived-mesenchymal Stem Cells Treatment for Patients With Decompensated Liver Cirrhosis Recruiting NCT03945487 Phase 2
22 Phase II Study of Combination Stereotactic Body Radiotherapy (SBRT) With Transarterial Chemo-Embolization (TACE) for Unresectable Hepatocellular Carcinoma Terminated NCT01020812 Phase 1, Phase 2
23 Treatment of Hepatic Encephalopathy With Benzodiazepine Antagonist (Flumazenil) and Change in Cortical GABA Levels in Localized 1H-MR Spectroscopy Withdrawn NCT02048969 Phase 1, Phase 2 Flumazenil;Placebo
24 Phase 1 Study of Intrahepatic Reinfusion of Highly Purified CD133+ Stem Cells in Patients With End-Stage Liver Disease Unknown status NCT01025622 Phase 1
25 Open Label, Study to Determine the Pharmacokinetic Interactions of Steady State Tipranavir/Ritonavir (500/200 mg) and Steady State Ribavirin and Pegylated Interferon Alfa 2a in HIV Negative, HCV Infected Subjects With Mild Hepatic Impairment and the Pharmacokinetic Properties of Tipranavir/Ritonavir in HIV Negative, HCV, HBV, Hepatitis Delta Infected Subjects or Alcoholic Cirrhosis Subjects With Moderate Hepatic Impairment Completed NCT02259855 Phase 1 Tipranavir;Ritonavir;Pegylated interferon;Ribavirin
26 Probiotic LGG in Patients With Minimal Hepatic Encephalopathy Completed NCT00992290 Phase 1
27 Treatment of Unresectable Hepatocellular Cancer With Opioid Growth Factor: a Phase I Study Completed NCT00706576 Phase 1 Infusion of opioid growth factor
28 A Phase I, Open-Label, Single-Dose Study to Evaluate the Safety and Efficacy of Hepatic Artery Injection of Autologous Human Bone Marrow-Derived Mesenchymal Stem Cells (Cellgram™) in Patients With Alcoholic Liver Cirrhosis Recruiting NCT03838250 Phase 1
29 Genetical Predisposition in Hepatocellular Carcinoma : Pangenomic Link Study During Alcoholic Cirrhosis Unknown status NCT01065233
30 A Double-Blind, Randomized, Placebo-Controlled Study of the Effects of Daily Oral Zinc Sulfate (220 mg) in Subjects With Alcoholic Cirrhosis Unknown status NCT02072746
31 Measurement of Fibrinogen in Patients With Systemic Inflammatory Response Syndrome, Sepsis, Chronicle Liver Disease or After Lysis on Intensive Care Units Unknown status NCT01169168
32 Is Access to Liver Transplantation Similar in Alcoholic or Not Patients? A Prospective Cohort Study Unknown status NCT01820819
33 Prospective Analysis Of Cardiac Function In Cirrhotic Patients By Echocardiography And Its Correlation With Adverse Events Unknown status NCT01433848
34 A Prospective Multicenter Study of Acute on Chronic Liver Failure in China Unknown status NCT02457637
35 Evolution of Nutritional Status, Metabolic, Functional and Clinical Outcomes in Patients Undergoing Liver Transplantation Unknown status NCT02917382
36 A Watermelon Focused Dietary Inflammatory Index Counseling System to Reduce Systemic Inflammation Unknown status NCT03158740
37 Adipose Tissue Involvement in Alcohol-induced Liver Inflammation in Human : Study of Pro- and Anti-inflammatory Cytokines and ADIPOKINES.. Completed NCT00388323
38 Randomized Trial Comparing Liver Transplantation to Alternative Therapies for Patients With Pugh B Alcoholic Cirrhosis Completed NCT00701792
39 Randomised Open-label Multicenter Study Evaluating Ciprofloxacin in Severe Alcoholic Hepatitis in Addition to Prednisolon Therapy Completed NCT02326103 Early Phase 1 Ciprofloxacin;Placebo
40 Makuuchi Versus Barcelona Clinic of Liver Cancer Criteria in Cirrhotic Patients With Hepatocellular Carcinoma. Does Etiology of Cirrhosis Influence the Relationship Between the Portal Pressure and Quantitative Tests of Liver Function? Completed NCT00827723
41 Acoustic Liver Biopsy in Normals and in Patients With Cirrhosis Using Endoscopic Ultrasound. Completed NCT01208311
42 Probiotic Modulation of Gut Microflora in Cirrhosis: Influence on Immune Function and Infections Completed NCT01607528
43 Impact of Alcohol Consumption of the General Population Who Visited Primary Health Care Centers on the Use of Health Care Resources in Catalonia. Completed NCT02343874
44 Metabolic and Nutritional Assessment in Patients on the Waiting List for Liver Transplantation Completed NCT01761851
45 Obesity - Inflammation - Metabolic Disease: Effect of Lactobacillus Casei Shirota Completed NCT01182844
46 Prognostic Value of Liver Volume on Acute Decompensation of Alcoholic Cirrhosis, a Prospective Multicenter Observational Study Recruiting NCT03508388
47 A Study of Molecular and Genetic Factors for Liver Cancer in the Greater Baltimore Area Recruiting NCT00913757
48 Profermin®: Prevention of Progression in Alcoholic Liver Disease by Modulating Dysbiotic Microbiota - a Randomized Controlled Clinical Trial Recruiting NCT03863730
49 A Randomized, Pragmatic, Outcome-assessor-blinded Study of an SMS-message-based Lifestyle Intervention in Patients With Decompensated Liver Cirrhosis Recruiting NCT02811887
50 Comparison of Inflammatory Profiles and Regenerative Potential in Alcoholic Liver Disease Recruiting NCT03773887

Search NIH Clinical Center for Alcoholic Liver Cirrhosis

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Alcoholic Liver Cirrhosis cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Alcoholic Liver Cirrhosis:
Livercellgram, bone marrow-derived mesenchymal stem cells for treatment of alcoholic liver cirrhosis
Embryonic/Adult Cultured Cells Related to Alcoholic Liver Cirrhosis:
Bone marrow-derived mesenchymal stem cells

Cochrane evidence based reviews: liver cirrhosis, alcoholic

Genetic Tests for Alcoholic Liver Cirrhosis

Anatomical Context for Alcoholic Liver Cirrhosis

MalaCards organs/tissues related to Alcoholic Liver Cirrhosis:

41
Liver, Skin, Bone, Testes, Kidney, Monocytes, T Cells
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Alcoholic Liver Cirrhosis:
# Tissue Anatomical CompartmentCell Relevance
1 Liver Liver Lobule Hepatocytes Affected by disease

Publications for Alcoholic Liver Cirrhosis

Articles related to Alcoholic Liver Cirrhosis:

(show top 50) (show all 1323)
# Title Authors PMID Year
1
Association of polymorphism in alcohol dehydrogenase and interaction with other genetic risk factors with alcoholic liver cirrhosis. 9 38
20171022 2010
2
Polymorphism in cytochrome P450 2E1 and interaction with other genetic risk factors and susceptibility to alcoholic liver cirrhosis. 9 38
19428381 2009
3
Polymorphism in glutathione-S-transferases: a risk factor in alcoholic liver cirrhosis. 9 38
19157724 2009
4
Human serum fetuin A/alpha2HS-glycoprotein level is associated with long-term survival in patients with alcoholic liver cirrhosis, comparison with the Child-Pugh and MELD scores. 9 38
17394649 2007
5
[Serum cytokine concentration as prognostic factor in patients with alcoholic liver disease]. 9 38
17036498 2006
6
[Genetic polymorphisms of alcohol-metabolizing enzymes and cytokines in patients with alcohol induced pancreatitis and alcoholic liver cirrhosis]. 9 38
15220553 2004
7
New concepts of the pathogenesis of alcoholic liver disease lead to novel treatments. 9 38
14720455 2004
8
[Effects of genetic polymorphisms of ethanol-metabolizing enzymes on alcohol drinking behaviors]. 9 38
12824748 2003
9
[Studies on the mechanism of elevation of serum PIVKA-II levels in alcoholic liver cirrhosis]. 9 38
11985059 2002
10
Serum leptin levels in alcoholic liver cirrhosis: relationship with gender, nutritional status, liver function and energy metabolism. 9 38
11641747 2001
11
Hepatitis C and the leptin system: bound leptin levels are elevated in patients with hepatitis C and decrease during antiviral therapy. 9 38
11336170 2001
12
Serum cytokine levels in alcohol-related liver cirrhosis. 9 38
11282449 2001
13
Alcohol-related cirrhosis with pancreatitis. The role of oxidative stress in the progression of the disease. 9 38
11348018 2001
14
Serum levels of cytokines in alcoholic liver cirrhosis and pancreatitis. 9 38
11059648 2000
15
N-acetyltransferase-2, glutathione S-transferase M1, alcohol dehydrogenase, and cytochrome P450IIE1 genotypes in alcoholic liver cirrhosis: a case-control study. 9 38
10232877 1999
16
[Liver function and the level of total cholesterol in the blood serum in liver cirrhosis]. 9 38
10204356 1998
17
Oxidative stress in the liver and biliary tract diseases. 9 38
9867111 1998
18
Plasminogen in patients with liver cirrhosis. 9 38
9253235 1997
19
Plasma glutathione S-transferase alpha 1-1 levels in patients with chronic liver disorders. 9 38
9049444 1997
20
Polymorphisms in alcohol metabolizing enzyme genes and alcoholic cirrhosis in Japanese patients: a multivariate analysis. 9 38
7557863 1995
21
Altered expression of monocyte IgA Fc receptors is associated with defective endocytosis in patients with alcoholic cirrhosis. Potential role for IFN-gamma. 9 38
7636220 1995
22
Genotypes of alcohol-metabolizing enzymes in Mexicans with alcoholic liver cirrhosis. 9 38
8845660 1995
23
[Blood chemistry, hematology of patients with liver cirrhosis]. 9 38
8114309 1994
24
Erythrocyte antioxidant activity, serum ceruloplasmin, and trace element levels in subjects with alcoholic liver disease. 9 38
1575205 1992
25
[Membrane cholesterol and insulin receptor in erythrocytes]. 9 38
1774014 1991
26
Sepsis-related Organ Failure Assessment Score is a strong predictor of survival in acute-on-chronic liver failure. 38
31315795 2019
27
Intraabdominal Hemorrhage from Ruptured Ectopic Varices Treated by Antegrade Embolization via a Recanalized Paraumbilical Vein. 38
31073821 2019
28
Number of hospital contacts with alcohol problems predicts later risk of alcoholic liver cirrhosis. 38
29528775 2019
29
Combined Effects of Alcohol and Metabolic Disorders in Patients With Chronic Liver Disease. 38
31255807 2019
30
Right anterior section graft for living-donor liver transplantation: A case report. 38
31083154 2019
31
Dabigatran causing severe acute kidney injury in a patient with liver cirrhosis. 38
30659506 2019
32
Value of gadoxetic acid-enhanced MRI and diffusion-weighted imaging in the differentiation of hypervascular hyperplastic nodule from small (<3 cm) hypervascular hepatocellular carcinoma in patients with alcoholic liver cirrhosis: A retrospective case-control study. 38
31062483 2019
33
De Novo Hepatitis B Virus Infection After Liver Transplantation in Hepatitis B Core-positive Recipients Using Hepatitis B Core-negative Grafts. 38
30979473 2019
34
Genomic Features, Comparative Genomic Analysis, and Antimicrobial Susceptibility Patterns of Chryseobacterium arthrosphaerae Strain ED882-96 Isolated in Taiwan. 38
31010035 2019
35
Factors influencing serum chemerin and kallistatin concentrations in patients with alcohol-induced liver cirrhosis. 38
30922045 2019
36
Granulocytic myeloid-derived suppressor cell population increases with the severity of alcoholic liver disease. 38
30585398 2019
37
A case of fatal cutaneous caput medusae hemorrhage. 38
30899470 2019
38
TM6SF2 and MBOAT7 Gene Variants in Liver Fibrosis and Cirrhosis. 38
30875804 2019
39
Myelopathy due to human T-cell leukemia virus type-1 from the donor after ABO-incompatible liver transplantation. 38
31029562 2019
40
Continuing Medical Education Questions: February 2019. 38
30730322 2019
41
Opportunities to Prevent Alcoholic Liver Cirrhosis in High-Risk Populations: A Systematic Review With Meta-Analysis. 38
30353053 2019
42
[Acquired hemophilia A with high-titer factor VIII inhibitor developing subsequent to clopidogrel administration]. 38
31068558 2019
43
Successful definitive concurrent chemoradiotherapy in a patient with esophageal cancer and Child-Pugh B cirrhosis of the liver. 38
30880788 2019
44
Postoperative Portomesenteric Venous Thrombosis After Colorectal Cancer Surgery. 38
30671797 2019
45
[Dissolution and maintenance of portal vein thrombosis with antithrombin III and edoxaban in liver cirrhosis:a case report]. 38
31178582 2019
46
Supraumbilical skin necrosis after repeat transarterial chemoembolization. 38
30449117 2019
47
Renal aspergillosis in a liver transplant patient: A case report and review of literature. 38
30613674 2018
48
Health literacy levels in outpatients with liver cirrhosis. 38
30621470 2018
49
Intraoperative Management of a Patient With Impaired Cardiac Function Undergoing Simultaneous ABO-Compatible Liver and ABO-Incompatible Kidney Transplant From 2 Living Donors: A Case Report. 38
30471833 2018
50
Aldehyde dehydrogenase 2 polymorphism affects the outcome of methanol poisoning in exposed humans. 38
29968299 2018

Variations for Alcoholic Liver Cirrhosis

Expression for Alcoholic Liver Cirrhosis

Search GEO for disease gene expression data for Alcoholic Liver Cirrhosis.

Pathways for Alcoholic Liver Cirrhosis

Pathways related to Alcoholic Liver Cirrhosis according to GeneCards Suite gene sharing:

(show all 15)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.86 PNPLA3 GSTM1 GPT CYP2E1 CYP2A6 ALDH2
2
Show member pathways
12.95 GSTM1 CYP2E1 CYP2A6 ALDH2 ADH4 ADH1C
3
Show member pathways
12.42 ALDH2 ADH4 ADH1C ADH1B
4
Show member pathways
12.23 GSTM1 CYP2E1 CYP2A6 ALDH2 ADH4 ADH1C
5 11.89 HGF GSTM1 CYP2A6
6
Show member pathways
11.66 CYP2E1 CYP2A6 ALDH2 ADH1B
7
Show member pathways
11.55 GSTM1 CYP2E1 CYP2A6
8 10.92 GSTM1 CYP2E1 CYP2A6
9 10.83 CYP2E1 CYP2A6
10
Show member pathways
10.67 ALDH2 ADH4 ADH1B
11 10.61 ADH1C ADH1B
12
Show member pathways
10.61 CYP2E1 ALDH2 ADH1B
13
Show member pathways
10.42 ALDH2 ADH4 ADH1C ADH1B
14
Show member pathways
10.37 CYP2E1 CYP2A6 ADH1B
15 10.23 GSTM1 CYP2E1

GO Terms for Alcoholic Liver Cirrhosis

Cellular components related to Alcoholic Liver Cirrhosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 blood microparticle GO:0072562 9.13 F2 ALB AHSG
2 platelet alpha granule lumen GO:0031093 8.8 HGF ALB AHSG

Biological processes related to Alcoholic Liver Cirrhosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 oxidation-reduction process GO:0055114 9.5 SOD2 CYP2E1 CYP2A6 ALDH2 ADH4 ADH1C
2 exogenous drug catabolic process GO:0042738 9.43 CYP2E1 CYP2A6
3 platelet degranulation GO:0002576 9.43 HGF ALB AHSG
4 drug metabolic process GO:0017144 9.4 CYP2E1 CYP2A6
5 organic acid metabolic process GO:0006082 9.37 CYP2E1 CYP2A6
6 epoxygenase P450 pathway GO:0019373 9.32 CYP2E1 CYP2A6
7 alcohol metabolic process GO:0006066 9.16 ALDH2 ADH4
8 ethanol oxidation GO:0006069 8.92 ALDH2 ADH4 ADH1C ADH1B

Molecular functions related to Alcoholic Liver Cirrhosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 oxidoreductase activity GO:0016491 9.5 SOD2 CYP2E1 CYP2A6 ALDH2 ADH4 ADH1C
2 oxidoreductase activity, acting on the aldehyde or oxo group of donors, NAD or NADP as acceptor GO:0016620 9.37 ALDH2 ADH4
3 retinol dehydrogenase activity GO:0004745 9.32 ADH4 ADH1C
4 arachidonic acid epoxygenase activity GO:0008392 9.26 CYP2E1 CYP2A6
5 alcohol dehydrogenase (NAD) activity GO:0004022 9.16 ADH4 ADH1C
6 alcohol dehydrogenase activity, zinc-dependent GO:0004024 8.8 ADH4 ADH1C ADH1B

Sources for Alcoholic Liver Cirrhosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....